DEF 14A: ARS Pharmaceuticals Sets Date for 2024 Annual Stockholders Meeting

ARS Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to elect directors and ratify the selection of Ernst & Young LLP as its independent accounting firm.

Summary

• ARS Pharmaceuticals, Inc. will hold its 2024 Annual Meeting of Stockholders on June 20, 2024, at 9:00 a.m. Pacific Time in a virtual format.
• The meeting will include the election of three Class I directors for three-year terms expiring at the 2027 Annual Meeting.
• Stockholders will also vote to ratify the selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The record date for determining stockholders eligible to vote is April 24, 2024.
• Stockholders can attend and participate in the meeting online by visiting www.proxydocs.com/SPRY, where they can listen to the meeting live, submit questions, and vote.
• Advance registration is required by June 19, 2024, at 5:00 p.m. Eastern Time to participate, vote, or submit questions during the Annual Meeting.
• The Board of Directors recommends voting FOR the election of all director nominees and FOR the ratification of Ernst & Young LLP as the independent accounting firm.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It outlines routine corporate governance matters, so the sentiment is moderately positive due to the procedural nature and lack of negative indicators.

Positives

• The virtual format of the Annual Meeting aims to facilitate stockholder attendance and participation from any location.
• Stockholders have the opportunity to communicate with the Board of Directors and management by submitting questions in advance and during the meeting.
• The Board of Directors is actively seeking a balance of skills, knowledge, and diversity among its members.
• The Audit Committee is committed to overseeing the company's accounting and financial reporting processes.

Risks

• Failure to achieve a quorum of stockholders could result in adjournment of the Annual Meeting.
• If stockholders do not provide voting instructions to their brokers, their shares may not be voted on certain proposals.
• There is a risk that any other matters properly brought before the Annual Meeting could lead to unforeseen outcomes.

Future Outlook

The document outlines the procedures and proposals for the upcoming Annual Meeting, focusing on governance and director elections, with no specific financial forecasts or guidance provided.

Management Comments

• Our Board of Directors recommends a vote FOR the election of all its nominees for director to our Board of Directors and FOR the ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.

Industry Context

This announcement is a standard corporate governance procedure for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions such as electing directors and ratifying the selection of auditors.

Comparison to Industry Standards

• Holding annual meetings, electing directors, and ratifying auditors are standard practices for publicly traded companies like ARS Pharmaceuticals.
• Virtual annual meetings have become increasingly common, especially among companies listed on Nasdaq, offering broader accessibility to stockholders.
• The director nomination process and board diversity considerations align with current corporate governance trends, similar to practices at companies like Amgen (AMGN) and Gilead Sciences (GILD).

Related Party Transactions

• In April 2021, Private ARS Pharma entered into a consulting agreement, as amended on April 25, 2022 (as amended, the Saunders Consulting Agreement), with Mr. Saunders, who was then serving as a member of Private ARS Pharmas board of directors, pursuant to which Mr. Saunders provided general advice and assistance to Private ARS Pharma with respect to the development of its current and future product candidates.
• In September 2018, Private ARS Pharma entered into a consulting agreement (the Marlinspike Consulting Agreement) with Marlinspike Group, LLC (Marlinspike).
• Dr. Shah, who served as the chair of Private ARS Pharmas board of directors prior to the November 2022 merger and currently serves as our Chair, is the President of Marlinspike, which provides management and business consulting services as well as business development support to us for a monthly fee of $20,000.
• Mr. Chakma, our Chief Business Officer is a consultant of Marlinspike.
• In September 2015, Private ARS Pharma entered into a consulting agreement (the 2015 PLC Consulting Agreement) with Pacific-Link Consulting LLC (PLC).
• Mr. Lowenthal, our President and Chief Executive Officer and member of our Board of Directors, and Dr. Tanimoto, our Chief Medical Officer, are the owners of PLC, which provides general advice and assistance to us with respect to the development of current and future drug products.
• In addition, Sarah Lowenthal, the daughter of Mr. Lowenthal and Dr. Tanimoto, is employed by PLC.
• On July 1, 2022, Private ARS Pharma entered into a revised consulting agreement with PLC (the 2022 PLC Consulting Agreement) that superseded the 2015 PLC Consulting Agreement.

Stakeholder Impact

• Stockholders have the opportunity to vote on key decisions, influencing the company's direction.
• Employees are indirectly affected by the election of directors and the ratification of the accounting firm.
• The outcome of the meeting could impact the company's reputation and investor confidence.

Next Steps

• Stockholders are urged to cast their vote as soon as possible via the internet, telephone, or mail.
• The company will file a Form 8-K to publish the final voting results within four business days after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Board of Directors, Director Election, Ernst & Young, Ratification, Virtual Meeting, Corporate Governance, ARS Pharmaceuticals